Afficher la notice abrégée

dc.contributor.authorGarcía Sanz, Ramón 
dc.contributor.authorHernández, J. M.
dc.contributor.authorCaballero, M. D.
dc.contributor.authorGonzález Díaz, Marcos 
dc.contributor.authorGalende, J
dc.contributor.authorCañizo Fernández-Roldán, María Consuelo del
dc.contributor.authorVázquez López, María Lourdes 
dc.contributor.authorSan Miguel Izquierdo, Jesús Fernando
dc.date.accessioned2024-02-01T21:09:37Z
dc.date.available2024-02-01T21:09:37Z
dc.date.issued1993-12
dc.identifier.citationGarcia, R., Hernandez, J. M., Caballero, M. D., González, M., Galende, J., Del Canizo, M. C., ... & San Miguel, J. F. (1993). Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. British journal of cancer, 68(6), 1227-1231.es_ES
dc.identifier.issn0007-0920
dc.identifier.urihttp://hdl.handle.net/10366/155189
dc.descriptionEste trabajo permitió consolidar la relevancia de la LDH como factor pronóstico en el linfoma de Hodgkin, algo utilizado después para predecir el pronóstico de estos pacientes en nuestro servicio durante muchos años. Además, sirvió para iniciar la carrera del autor y una línea de investigación del Servicio de hematología que actualmente ha permitido a dicho servicio ser la referencia nacional en esta enfermedad, incluyendo tanto el desarrollo del trasplante Haploidéntico y el diseño de los ensayos clínicos más relevantes sobre esta patología en Españaes_ES
dc.description.abstract[EN]The efficacy of currently available treatments for Hodgkin's disease (HD) has led to a substantial modification in the prognosis of this disease; nevertheless there is still a group of patients that cannot be cured with conventional treatments and who will be candidates for alternative therapy. In the present work we analysed the prognostic influence of the most relevant clinico-biological characteristics of HD in a consecutive series of 137 patients diagnosed and treated in a single institution. Univariate analyses identified six variables with significant prognostic influence, both on achieving complete remission (CR) and overall survival (OS); LDH > 320 U ml-1, age > 45 years, stages IIB, III and IV, extranodal involvement, alkaline phosphatase > 190 UI dl and ESR > 40 mm h. In addition, Hb < 12.5 gr dl-1 and abdominal disease were statistically relevant for CR while a poor performance score (ECOG > or = 2) affected a lower survival. In the multivariate analysis only LDH, age and the clinical stage retained a significant prognostic influence for achieving CR, while the two first factors above, together with performance status were the variables with independent prognostic value with respect to OS. Moreover, only LDH > 320 U ml-1 had prognostic influence in the probability of relapse and disease free survival (DFS), both in the univariate and multivariate analyses. According to the three independent factors obtained in the multivariate analysis for CR (LDH, age and stage) a predictive model was established that allows the stratification of patients into two prognostic groups: one with poor prognosis that includes patients with the three adverse prognostic factors, or two if one of them was elevated LDH, and the other with good prognosis that includes the remaining patients. This model was also able to separate two independent groups of patients with respect to OS and to DFS. In conclusion, the present study shows that LDH is one of the most important prognostic factors in HD.es_ES
dc.description.sponsorshipHospital Universitario de Salamanca Universidad de Salamancaes_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.subjectLymphoma prognosis LDHes_ES
dc.subject.meshAlkaline Phosphatase *
dc.subject.meshAged *
dc.subject.meshAnalysis of Variance *
dc.subject.meshClinical Enzyme Tests *
dc.subject.meshHumans *
dc.subject.meshAdolescent *
dc.subject.meshHodgkin Disease *
dc.subject.meshHematocrit *
dc.subject.meshMiddle Aged *
dc.subject.meshNeoplasm Staging *
dc.subject.meshL-Lactate Dehydrogenase *
dc.subject.meshPredictive Value of Tests *
dc.subject.meshChi-Square Distribution *
dc.subject.meshTreatment Outcome *
dc.subject.meshRegression Analysis *
dc.subject.meshSurvival Analysis *
dc.subject.meshSurvival Rate *
dc.titleSerum lactate dehydrogenase level as a prognostic factor in Hodgkin's diseasees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://www.nature.com/articles/bjc1993509es_ES
dc.subject.unesco3205.04 Hematologíaes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccesses_ES
dc.journal.titleBritish Journal of Canceres_ES
dc.volume.number68es_ES
dc.issue.number6es_ES
dc.page.initial1227es_ES
dc.page.final1231es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decshematocrito *
dc.subject.decsanálisis de regresión *
dc.subject.decshumanos *
dc.subject.decsanciano *
dc.subject.decsmediana edad *
dc.subject.decsenfermedad de Hodgkin *
dc.subject.decsadolescente *
dc.subject.decsestadificación de neoplasias *
dc.subject.decspruebas de valores predictivos *
dc.subject.decsfosfatasa alcalina *
dc.subject.decstasa de supervivencia *
dc.subject.decsresultado del tratamiento *
dc.subject.decsanálisis de la varianza *
dc.subject.decsdistribución de la ji al cuadrado *
dc.subject.decsanálisis de supervivencia *
dc.subject.decspruebas enzimáticas clínicas *
dc.subject.decsl-lactato deshidrogenasa *
dc.description.projectHospital Universitario de Salamancaes_ES


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée